Understanding the Causes of Antimicrobial Resistance

Antimicrobial resistance is not a distant threat-it’s happening right now, in hospitals, communities, and farms worldwide. Every time bacteria, fungi, and other microorganisms develop the ability to defeat the drugs designed to kill them, infections become harder to treat. According to the World Health Organization, bacterial AMR was directly responsible for 1.27 million global deaths in 2019, with projections suggesting this number could surge to 10 million annually by 2050 if current trends continue. Understanding what drives this silent pandemic is the first step toward protecting public health and preserving the effectiveness of our life-saving medications.

Overuse and misuse of antimicrobial drugs
Agricultural practices and livestock production
Poor infection prevention and control
Lack of new drug development
The intersection of multiple factors
Moving toward solutions

Overuse and misuse of antimicrobial drugs

The primary driver of antimicrobial resistance is the excessive and inappropriate use of antibiotics and antifungals in human medicine. The CDC reports that at least 30% of antibiotic use in the United States is unnecessary, meaning millions of prescriptions are written for conditions that don’t require them, such as viral infections like colds and flu.

This misuse takes several forms. Patients often stop taking antibiotics as soon as they feel better rather than completing the prescribed course, leaving behind surviving bacteria that may develop resistance. Healthcare providers sometimes prescribe broad-spectrum antibiotics when narrower options would suffice, or they prescribe antibiotics without adequate testing to confirm bacterial infection. In fact, about one-third of hospital patients receive antibiotic prescriptions without adequate testing, and these prescriptions often continue for longer than necessary.

The problem extends beyond hospitals. In many countries, antibiotics are available over the counter without a prescription, enabling self-medication and contributing to resistance. Poor-quality or counterfeit antibiotics in the supply chain further worsen the situation, as substandard formulations create conditions where bacteria can adapt and survive.

Global antibiotic consumption in humans increased by 65% between 2000 and 2015, driven largely by rising incomes in developing countries. If nothing changes, antibiotic consumption is projected to increase by 200% between 2015 and 2030.

Agricultural practices and livestock production

Agriculture represents another major source of antimicrobial resistance. The WHO notes that antibiotics are frequently used in livestock to promote growth and prevent disease, even in healthy animals, creating conditions where resistant bacteria can develop and spread.

The scale of agricultural antibiotic use is staggering. Approximately 70% of medically important antibiotics sold in the United States are used in animals raised for food. These antibiotics are often the same classes or have similar mechanisms to those used in human medicine, creating direct pathways for resistance to transfer between animals and humans.

Transmission occurs through multiple routes. People can be exposed to resistant bacteria through direct contact with animals, consumption of undercooked meat, handling uncooked meat, or exposure to contaminated water and soil. Animal waste used as fertilizer contains antibiotic residues and resistant bacteria, which can contaminate agricultural lands, water sources, and crops.

Even agricultural pesticides contribute to the problem. Triazole fungicides, widely used on crops, are similar to antifungal medicines used in humans. The use of these fungicides increased more than fourfold from 2006 to 2016 in the United States alone, potentially compromising treatment options for fungal infections in humans.

Poor infection prevention and control

Inadequate infection control measures in healthcare facilities accelerate the spread of resistant organisms. When hospitals and clinics fail to implement proper hygiene protocols, antimicrobial-resistant germs easily spread between patients, healthcare workers, and the broader community.

The problem is particularly acute in resource-limited settings. Many countries lack adequate water, sanitation, and hygiene infrastructure, creating environments where resistant bacteria can thrive and spread. Globally, more than 2 billion people lacked access to basic sanitation in 2017, and 780 million did not have access to at least basic water services.

Healthcare-associated infections provide ideal conditions for resistance to emerge and spread. When sick, vulnerable patients are exposed to antibiotics in hospital settings, resistant bacteria have ample opportunity to multiply and transfer between individuals. Studies have found measurable levels of antimicrobial-resistant bacteria in wastewater from hospitals and communities, which can contaminate surface waters and contribute to environmental spread.

The situation is compounded by global travel and trade. Modern travel means antimicrobial resistance can easily spread across borders, with more than 410 million travelers arriving in the United States alone through more than 300 points of entry each year. Travelers can unknowingly carry resistant organisms for up to 12 months after visiting areas with high rates of resistance.

Lack of new drug development

While resistance continues to spread, the pipeline of new antibiotics has nearly run dry. The number of antibiotics in clinical development fell from 97 in 2023 to 90 in 2025, and most of these are not truly innovative-they’re modifications of existing drugs that bacteria may already have mechanisms to resist.

The problem is economic. There are now just 3,000 active antimicrobial resistance researchers globally, compared to nearly 46,000 in oncology. Pharmaceutical companies have largely abandoned antibiotic development because these drugs must be used sparingly to preserve their effectiveness, limiting sales volumes and profitability.

When companies do develop new antibiotics and receive regulatory approval, they often struggle to survive financially. Of 12 antibiotics companies that went public in the past decade, only 5 remain active today. One company went bankrupt within a year of getting a new antibiotic approved. Without consistent market support, talented researchers leave the field entirely-90% by their second job change after a company shuts down an antimicrobial resistance program.

The consequences are severe. Only 15 antibiotics in clinical development qualify as innovative, and only 5 are effective against at least one critical priority pathogen identified by WHO. This leaves healthcare providers with dwindling treatment options for serious infections, particularly those caused by carbapenem-resistant bacteria and multidrug-resistant tuberculosis.

The intersection of multiple factors

These causes don’t exist in isolation-they interact and amplify each other. Overuse of antibiotics in agriculture creates resistant bacteria that spread to humans through food and water. Poor sanitation accelerates transmission within communities. Healthcare settings without adequate infection control become amplifiers of resistance. And the lack of new drugs means we have fewer options when resistance emerges.

The spread of resistance is also accelerated by modern life. Resistant bacteria can share their resistance genes with other bacteria through horizontal gene transfer, making the infections they cause more difficult or impossible to treat. This genetic sharing happens readily in environments where different bacteria encounter each other, such as in wastewater, agricultural settings, and healthcare facilities.

Knowledge gaps contribute significantly to the problem. Many healthcare workers and members of the public lack adequate understanding of appropriate antibiotic use and resistance mechanisms. In some countries, farmers believe antibiotics can treat all animal diseases, even though many understand that misuse causes resistance. Without proper education and surveillance systems to track antibiotic use and resistance patterns, effective interventions remain difficult to implement.

Moving toward solutions

Addressing antimicrobial resistance requires coordinated action across multiple sectors. Healthcare providers must improve prescribing practices and ensure antibiotics are only used when truly needed. The agricultural sector needs to phase out routine antibiotic use for growth promotion and disease prevention in healthy animals. Healthcare facilities must strengthen infection prevention and control measures. And significant investment is needed in research and development of new antimicrobials, diagnostics, and vaccines.

The good news is that solutions are within reach. Simple interventions like good hand hygiene, routine vaccination, safe food preparation, and improved sanitation can slow the spread of resistant organisms. Antimicrobial stewardship programs that optimize antibiotic prescribing have proven effective in healthcare settings. Countries that have implemented comprehensive action plans have seen reductions in both antibiotic use and resistance rates.

Success requires a “One Health” approach that recognizes the interconnections between human health, animal health, and the environment. It demands collaboration between governments, healthcare systems, agricultural industries, researchers, and communities. Most importantly, it requires sustained commitment and adequate resources to implement proven interventions at scale.

What do you think? How can we better balance the need for antimicrobials to treat infections with the imperative to preserve their effectiveness for future generations? What role should individuals, healthcare providers, and policymakers each play in addressing this global health challenge?

References

PDF 📄

Table of Contents

Overuse and misuse of antimicrobial drugs 🔗

Agricultural practices and livestock production 🔗

Poor infection prevention and control 🔗

Lack of new drug development 🔗

The intersection of multiple factors 🔗

Moving toward solutions 🔗